Plavix (Clopidogrel) is an antiplatelet agent used to reduce the risk of stroke or heart attack in patients with atherosclerosis. Plavix (Clopidogrel) is an inhibitor of platelet aggregation. A variety of drugs that inhibit platelet function have been shown to decrease morbid events in people with established atherosclerotic cardiovascular disease as evidenced by stroke or transient ischemic attacks, myocardial infarction, or need for bypass or angioplasty. This indicates that platelets participate in the initiation and/or evolution of these events and that inhibiting them can reduce the event rate. Plavix (Clopidrogel) selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor and the subsequent A.P. mediated activation of the glycoprotein GPIIb/ IIIa complex, thereby inhibiting platelet aggregation. Biotransformation of clopidogrel is necessary to produce inhibition of platelet aggregation, but an active metabolite responsible for the activity of the drug has not been isolated. Plavix (Clopidogrel) also inhibits platelet aggregation induced by agonists other than ADP by blocking the amplification of platelet activation by released A.P. Plavix (Clopidogrel) does not inhibit phosphodiesterase activity.
Plavix (Clopidogrel) acts by irreversibly modifying the platelet ADP receptor. Consequently, platelets exposed to Plavix (Clopidogrel) are affected for the remainder of their lifespan. Dose dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses of Plavix (Clopidogrel). Repeated doses of 75 mg Plavix (Clopidogrel) per day inhibit A.P. induced platelet aggregation on the first day, and inhibition reaches steady state between Day 3 and Day 7. At steady state, the average inhibition level observed with a dose of 75 mg Plavix (Clopidogrel) per day was between 40% and 60%. Platelet aggregation and bleeding time gradually return to baseline values after treatment is discontinued, generally in about 5 days.
As with other anti- platelet agents, Plavix (Clopidogrel) should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery, or other pathological conditions. If a patient is to undergo elective surgery and an antiplatelet effect is not desired, PLAVIX should be discontinued 7 days prior to surgery.
ADDITIONAL MONITORING OF YOUR DOSE of Plavix (Clopidogrel) OR CONDITION may be needed if you are taking medicines such as ibuprofen or naproxen (NSAIDs), warfarin, heparin, phenytoin, tamoxifen, tolbutamide, torsemide, and fluvastatin. Plavix (Clopidogrel) may be taken on an empty stomach or with food. STORE PLAVIX at room temperature, away from heat and light. PLAVIX may be taken on an empty stomach or with food. STORE Plavix (Clopidogrel) at room temperature, away from heat and light. Plavix (Clopidogrel) is indicated for the reduction of thrombotic events as follows:
Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease,Plavix (Clopidogrel) has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
Acute Coronary Syndrome
For patients with acute coronary syndrome (unstable angina/non-Q-wave MI), including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG,Plavix (Clopidogrel) has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.
Candrug.com supplies only genuine Plavix from Canada and Turkey shipped using Canadian and Turkish packaging. This Plavix is manufactured by Bristol-Myers Squibb the worldwide manufacturer of Plavix. This offer is neither endorsed nor authorized by Bristol-Myers Squibb (the United States and Canadian distributor of Plavix). Candrug.com has no affiliation whatsoever with Bristol-Myers Squibb.
PLAVIX side effects that may go away during treatment, include diarrhea or indigestion. CONTACT YOUR DOCTOR IMMEDIATELY if you experience PLAVIX side effects like sudden, severe, persistent headache; change in vision; rash; itching; nosebleeds; excessive bleeding from cuts; bleeding from gums when brushing teeth; increased menstrual bleeding; unexplained vaginal bleeding; unusual bruising; discoloration of urine or stool; black, tarry stools; sore throat or fever; weakness; speech problems; seizures; yellowing of the skin or eyes; or pale skin.
PLAVIX (clopidogrel bisulfate) is an inhibitor of A.P. induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent A.P. mediated activation of the glycoprotein GPIIb/ IIIa complex.
PLAVIX (clopidogrel bisulfate) is available as a pink, round, biconvex, film-coated tablet debossed with “75” on one side and “1171” on the other. Tablets are provided as follows: